The routine scheduling of classic targeted therapies commonly completely underestimates the diversity of tumor systems states and the important fact that activity profiles of single targeted drugs may context-dependently decisively change, as to be exemplified with mTor inhibitors (28–30). The gene discussed is MTOR; the disease is neoplasm.